Navidea moves forward with Alzheimer's Dx agent; Neuromodulation predicted to soar;

 @FierceMedDev: ArthroCAD draws Series A for surgical device development. Story | Follow @FierceMedDev

@MarkHFierce: Given Imaging ended exploration of a possible sale or merger--for now, the PillCam maker will go it alone. More | Follow @MarkHFierce

 @DamianFierce: Covidien wants to see if its Hawk devices can work in combo PAD treatment, a potentially lucrative market. Report | Follow @DamianFierce

> Phoenix Cardiac Devices enrolled its first patient in a CE mark-related clinical trial to test a device designed to treat mitral regurgitation without open-heart surgery. Item

> Navidea Biopharmaceuticals ($NAVB) completed another study of its NAV4694 imaging agent, designed to detect beta-amyloid deposits in the brain that can mark Alzheimer's development. The company also expanded its relationship with AstraZeneca ($AZN), licensing two more agents from the drugmaker. More

> Thermo Fisher ($TMO) snagged an expanded CE mark for its QMS Everolimus Assay Kit, clearing the diagnostic for use in liver transplants. The test is already green-lighted for heart and kidney procedures. News

> Pennyslvania's Rex Medical won the FDA's 510(k) clearance for its rotational thrombectomy system. Argon Medical Devices will market the technology in the U.S., European Union, Latin America, Canada and some Asia-Pacific countries. Release

> Venture capital giant Sequoia Capital has helped launch SV Bio, a new diagnostics company that will employ genomic data. Article | Release

> A new report predicts a $6.8 billion global neuromodulation device market by 2017. Story

> Millennium Research expects demand for continuous glucose monitoring devices, insulin pumps and pens to drive moderate growth in the U.S. diabetes care-related medical device market, hitting $16 billion by 2017. Release

Biotech News

 @FierceBiotech: Roche picks Sanford-Burnham chief to revive lagging research group. Story | Follow @FierceBiotech

@JohnCFierce: Looks like Mene Pangalos, champion of virtual development, eliminating fixed costs, comes out on top of AZ R&D. Release | Follow @JohnCFierce

@RyanMFierce: Pharma's got blockbuster hopefuls on the move in 2013, but a special lack of Alzheimer's meds in the mix. More | Follow @RyanMFierce

> Analysts pick the top blockbuster drug prospects in the class of '13. Report

> AstraZeneca research chief Mackay ousted in executive shakeup. News

Pharma News

@FiercePharma: Here's a novel job-preserving approach: U.K. politician urges NHS to use more of $AZN's Brilinta to stave off job cuts. More | Follow @FiercePharma

 @AlisonBFierce:Who gave you the flu? A new Facebook app helps you place the blame. Article | Follow @AlisonBFierce

> Forest's Lexapro plague lingers with 41% hit to Q3 sales. News

> New AZ chief sends top execs packing in management shuffle. Report

Biotech Research News

> Stem cells cut heart damage in muscular dystrophy mice. News

> Targeting VEGF could do more harm than good in the eye. More

> Stem cells show early promise in ALS. Item

Pharma Manufacturing News

> Private equity firm lays out $212 million for API maker. News

> Spain's Idifarma sweats the small stuff. Story

> New manufacturing issues lead AbbVie to 2nd Synthroid recall. Article

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.